España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

qualitec europa, s.l. - triflusal - excipientes: - agentes antitrombÓticos - inhibidores de la agregación plaquetaria, excluyendo heparina - triflusal

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

toll manufacturing services, s.l. - triflusal - excipientes: - agentes antitrombÓticos - inhibidores de la agregación plaquetaria, excluyendo heparina - triflusal

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

industria quimica y farmaceutica vir s.a. - triflusal - cÁpsula dura - 300 mg - triflusal 300 mg - triflusal

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios ern s.a. - triflusal - cÁpsula dura - 300 mg - triflusal 300 mg - triflusal

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios ern s.a. - triflusal - polvo y disolvente para soluciÓn oral - 600 mg - triflusal 600 mg - triflusal

Unión Europea - español - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil clorhidrato de - neoplasias colorrectales - agentes antineoplásicos - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.